
DMAC Stock Forecast & Price Target
DMAC Analyst Ratings
Bulls say
DiaMedica Therapeutics Inc. has reported encouraging interim Phase 2 results in its clinical program for preeclampsia, highlighting a statistically significant reduction in blood pressure without placental transfer, which strengthens the prospects for its product candidate DM199. This positive data has led to an increased price target, reflecting improved market confidence and the potential for substantial advancements in both preeclampsia and acute ischemic stroke treatment pathways. Furthermore, the favorable outcomes position DM199 favorably for future cohort enrollments, reinforcing the company's development strategy and prospects for future growth.
Bears say
DiaMedica Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock. Key concerns include the potential inability of its developmental candidates, DM199 and DM300, to meet projected peak commercial revenue estimates, which could stem from factors such as limited market size and penetration rates. Additionally, the company may struggle to secure adequate capital to fund ongoing operations and development, further complicating prospects for commercialization of its therapies.
This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DMAC Analyst Forecast & Price Prediction
Start investing in DMAC
Order type
Buy in
Order amount
Est. shares
0 shares